Sermorelin

Typical use cases

Dosing guidelines

Titration

Research and community protocols typically describe starting at the low end and adjusting gradually based on response and tolerability; bedtime timing is favored to align with the natural nocturnal GH pulse, and some users cite intermittent dosing (e.g., 5-on/2-off) to reduce potential receptor desensitization. Educational information only — not dosing guidance.

Reconstitution

Lyophilized powder reconstituted with bacteriostatic water (or sterile saline) for subcutaneous injection; the diluent is added slowly down the vial wall and swirled, not shaken

Injection sites

Subcutaneous injection, typically into abdominal fat (rotating sites); thigh and upper-arm fat also reported

Storage & handling

Lyophilized vials stored refrigerated at 2-8°C (36-46°F); once reconstituted, kept refrigerated and typically used within ~7-30 days depending on the preparation/preservative

Side effects

• Injection-site reaction (pain, swelling, redness) Mild · Common
• Headache Mild · Uncommon
• Facial flushing or warmth Mild · Uncommon
• Dizziness or drowsiness Mild · Uncommon
• Nausea or altered taste Mild · Rare
• Anti-sermorelin antibody formation (clinical relevance unclear) Moderate · Uncommon

Research summary

Sermorelin (GHRH 1-29) is the shortest fully active fragment of endogenous GHRH; it binds the GHRH receptor on anterior-pituitary somatotrophs to stimulate endogenous growth hormone release while remaining subject to somatostatin negative feedback, which is the basis for its often-cited theoretical safety advantage over exogenous recombinant hGH. The strongest human evidence is in pediatrics: it gained FDA approval in 1997 (marketed as Geref) for treating childhood growth-hormone deficiency and for diagnostic evaluation of pituitary function, with controlled studies describing improved height velocity at roughly 30 mcg/kg nightly. Foundational pharmacology work by Corpas and colleagues (1992) showed that twice-daily GHRH-(1-29) in healthy older men raised growth hormone and IGF-1 toward levels seen in younger men, and a frequently-referenced 2006 review by Walker argued sermorelin may better mimic youthful, pulsatile GH dynamics than rhGH in aging adults. The manufacturer discontinued the FDA-approved product in 2008 for commercial reasons, so today it exists almost entirely as a compounded preparation. Reported adult anti-aging, body-composition, sleep, and recovery benefits are largely drawn from small studies, mechanistic reasoning, and clinic/community reports rather than large randomized long-term trials. Key limitations include sparse modern controlled data in healthy adults, an extremely short half-life requiring frequent dosing, variable compounded-product quality, and unresolved questions about anti-sermorelin antibody formation. Overall the mechanism is well characterized, but rigorous outcome evidence outside pediatric GH deficiency remains limited.

Key references

• https://en.wikipedia.org/wiki/Sermorelin
• https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/
• https://pubmed.ncbi.nlm.nih.gov/1379256/
• https://www.rxlist.com/sermorelin-acetate-drug.htm
• https://pubchem.ncbi.nlm.nih.gov/compound/16132413

Related compounds